宫颈原位腺癌初始保守治疗后附加子宫切除术的成本效益分析
本研究基于荷兰1990至2021年回顾性队列,对1000例模拟患者比较保守治疗后附加子宫切除术与期待管理的成本效益。附加子宫切除术未增加质量调整生命年,成本升高863%,仅当假设子宫切除术无效用损失时QALY才有增加,成本效益比为€144,273,远高于€20,000阈值。结论认为附加子宫切除术不具成本效益。
要点
- 保守治疗后未行附加子宫切除术者中进展为宫颈癌的比例低于2%。
- 附加子宫切除术未获得QALY且成本升高863%(€6203,485 vs €644,238)。
- 仅当假设子宫切除术无效用损失时QALY才增加,成本效益比€144,273,远高于€20,000阈值。
核心结论
- 对于初始接受根治性LLETZ或CKC治疗、已完成生育的患者,附加子宫切除术不具成本效益。
研究设计与样本
- 基于荷兰1990至2021年回顾性队列的事后分析,纳入经根治性LLETZ或CKC保守治疗的宫颈原位腺癌患者,基于数据模拟1000例患者比较附加子宫切除术与期待管理的危害、获益和成本。
- 敏感性分析中变化了附加子宫切除术的时机、AIS治疗后复发高级别宫颈病变和宫颈癌风险、以及子宫切除术的效用损失。
主要发现
- 未接受附加子宫切除术的AIS患者中,进展为宫颈癌的比例低于2%。
- 附加子宫切除术未获得QALY,成本升高863%(€6203,485 vs €644,238)。
- 仅当假设子宫切除术无效用损失时QALY才有增加,成本效益比为€144,273,远高于€20,000的成本效益阈值。
关键数值与推荐
- 若干欧洲和美国指南推荐对初始接受保守治疗且在随访期间完成生育的宫颈原位腺癌患者行附加子宫切除术。
- 附加子宫切除术的成本效益比为€144,273,成本效益阈值为€20,000。
临床怎么用
- 对于初始接受根治性LLETZ或CKC保守治疗、已完成生育的AIS患者,附加子宫切除术不具成本效益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Several European and American guidelines recommend to perform an additional hysterectomy in patients with cervical adenocarcinoma in situ (AIS), who initially received conservative treatment and who completed childbearing during follow-up. This study aimed to evaluate cost-effectiveness of performing an additional hysterectomy in comparison to expectative management. METHODS: This post-hoc analysis was based on a retrospective cohort of patients diagnosed with AIS, who were conservatively treated by a radical (i.e., negative surgical margins) large loop excision of the transformation zone (LLETZ) or cold-knife conisation (CKC) in the Netherlands between 1990 and 2021. Based on these data, we estimated and compared the harms, benefits, and costs in 1000 simulated patients, both with and without an additional hysterectomy five years after conservative treatment for AIS. In the sensitivity analyses, we varied the timing of the additional hysterectomy, the risk of recurrent high-grade cervical dysplasia and cervical cancer risk after AIS treatment, and the utility loss for hysterectomy. RESULTS: Less than 2 % of the patients who did not receive an additional hysterectomy after AIS developed cervical cancer. When an additional hysterectomy was performed, no quality adjusted life-years (QALYs) were gained and costs were 863 % higher (€6203,485 versus €644,238). Only when assuming no utility loss for a hysterectomy, QALYs were gained resulting in a cost-effectiveness ratio of €144,273, which is far above the cost-effectiveness threshold of €20,000. CONCLUSION: It is not cost-effective to perform an additional hysterectomy after completion of childbearing in patients who were primarily treated by a radical LLETZ or CKC.
引用
- Schaafsma M, Schuurman TN, Siebers AG, et al. Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ. Gynecol Oncol. 2025. PMID: 39826428. doi:10.1016/j.ygyno.2025.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。